What Does SURMOUNT-3 Tell Us About the Cost-Effectiveness of Tirzepatide After Lifestyle Intervention?

At a glance

| Parameter | Detail | |---|---| | Trial | SURMOUNT-3 | | N | 579 (randomized 2:1 tirzepatide : placebo) | | Intervention | Tirzepatide (maximum tolerated dose, 10 mg or 15 mg) for 72 weeks | | Comparator | Placebo injection + continued lifestyle counseling | | Lead-in | 12-week intensive lifestyle intervention (low-calorie diet, 150 min/wk activity) | | Duration | 72 weeks (randomized phase) after 12-week lead-in | | Primary endpoint | Percent change in body weight from randomization to week 72 | | Key result | −21.1% (tirzepatide) vs −3.3% (placebo); treatment difference −18.4 pp |

Why SURMOUNT-3 Matters for Economic Modeling

Most cost-effectiveness analyses (CEAs) in obesity rely on trials where drug therapy begins de novo. SURMOUNT-3 broke that pattern. Every participant first completed a 12-week intensive lifestyle program and had already lost at least 5.0% of body weight before randomization. The clinical question was whether adding a GLP-1/GIP dual agonist on top of a proven behavioral response was worth it. The economic question is whether that incremental benefit, roughly 18 additional percentage points of weight loss, justifies the incremental cost.

That distinction matters for payers. Insurers often require documented lifestyle-intervention failure before covering anti-obesity medications. SURMOUNT-3 flips the premise: these patients succeeded at lifestyle change and still derived large additional benefit from tirzepatide. Modeling the value of pharmacotherapy in this population requires different baseline assumptions than trials enrolling treatment-naive participants.

List Price vs Net Price: The Numbers Behind the Gap

Eli Lilly launched Zepbound (tirzepatide for obesity) in late 2023 at a list price of roughly $1,060 per month, or about $12,720 annually at maintenance dosing. That figure, however, is the wholesale acquisition cost (WAC). Net prices after rebates and manufacturer discounts run substantially lower, particularly through Lilly's direct-to-consumer LillyDirect pharmacy program, which has offered vial formulations at roughly $399 to $549 per month for self-pay patients.

The gap between list and net matters enormously for CEA. A model using WAC will produce an incremental cost-effectiveness ratio (ICER) 40% to 60% higher than one using estimated net prices. Published analyses of semaglutide 2.4 mg (the closest comparator in the GLP-1 class) illustrate the sensitivity. A 2022 ICER (Institute for Clinical and Economic Review) report estimated semaglutide's cost-effectiveness at list price exceeded $150,000 per QALY but fell below $100,000 per QALY at modeled net prices incorporating rebates. Tirzepatide's slightly lower list price and larger effect size in SURMOUNT-3 shift the ratio favorably, but not enough to guarantee acceptability at the commonly cited $100,000/QALY threshold without net-price assumptions.

Modeling Framework: How CEA Applies to SURMOUNT-3

No standalone published CEA uses SURMOUNT-3 data exclusively, but several modeling groups have incorporated its results into broader tirzepatide value assessments. The general approach follows a Markov or microsimulation structure:

1. Health states are defined by BMI category and presence of obesity-related comorbidities (type 2 diabetes, cardiovascular events, obstructive sleep apnea, osteoarthritis).
2. Transition probabilities derive from weight trajectories observed in the trial. In SURMOUNT-3, 94.4% of tirzepatide-treated participants achieved ≥5% weight loss from randomization, and 62.9% achieved ≥20%, generating substantial shifts across BMI categories.
3. Comorbidity offsets are modeled from epidemiological data linking BMI reduction to incident disease risk. The AGA clinical practice guideline on pharmacological management of obesity cites 5% to 15% weight loss thresholds for clinically meaningful risk reduction in type 2 diabetes, hypertension, and MASLD. Most SURMOUNT-3 tirzepatide recipients exceeded those thresholds.
4. Time horizon and discontinuation are the most sensitive parameters. Weight regain after GLP-1 agonist discontinuation is well documented; the SURMOUNT-4 extension data showed roughly two-thirds of lost weight returned within 52 weeks of switching to placebo. Models assuming indefinite treatment generate higher total costs but also more sustained QALYs.

| Model Parameter | Conservative Estimate | Optimistic Estimate | |---|---|---| | Annual drug cost (net) | $8,500 | $5,000 | | Treatment duration | Lifetime | 3 years with taper | | Weight regain rate post-stop | 65% over 1 year | 30% with maintenance program | | Comorbidity cost offset (annual) | $1,200 | $3,800 | | Discount rate | 3% | 3% | | Modeled ICER ($/QALY) | $125,000, $175,000 | $55,000, $85,000 |

The spread is wide. This is not a weakness of the analysis but a reflection of real uncertainty in three variables: net drug cost, treatment duration, and the durability of weight loss.

What ICER's Review Tells Us About the GLP-1 Class

The Institute for Clinical and Economic Review published a 2022 assessment of anti-obesity medications that benchmarked semaglutide 2.4 mg and included tirzepatide in scenario analyses using SURMOUNT-1 data. ICER's base-case found that at WAC, both agents exceeded the $100,000/QALY threshold. At modeled net prices (approximately 40% discount), semaglutide approached acceptable ranges and tirzepatide performed slightly better per unit cost, given its larger treatment effect.

Updating those models with SURMOUNT-3 data introduces a favorable wrinkle. Because the trial population had already undergone structured lifestyle intervention, the incremental benefit of tirzepatide is being added to an optimized baseline. From a health-economic perspective, this means the comparator arm (lifestyle-only maintenance) is stronger than typical "usual care" comparators, which paradoxically can improve the ICER by reducing the placebo-arm QALY gains and widening the treatment difference. The 18.4 percentage-point weight separation in SURMOUNT-3 is the largest placebo-adjusted difference across the SURMOUNT program.

Payer Coverage: Current State and Policy Implications

Despite strong efficacy, insurance coverage for anti-obesity medications remains limited. Medicare Part D is statutorily excluded from covering weight-loss drugs, affecting over 60 million beneficiaries. Among commercial payers, coverage has expanded since 2023 but typically requires:

• BMI ≥30 (or ≥27 with comorbidity)
• Documentation of prior lifestyle intervention (often 6 months)
• Step therapy through older agents (phentermine, orlistat) before GLP-1 approval

SURMOUNT-3's design directly addresses the lifestyle-documentation requirement. The 12-week lead-in mirrors what payers request, and the data show that lifestyle responders still gain an additional 18 percentage points of weight loss with tirzepatide. For prior-authorization departments, this trial provides the cleanest evidence that lifestyle "success" does not eliminate the need for pharmacotherapy.

The Treat and Reduce Obesity Act, reintroduced in Congress multiple times, would lift Medicare's anti-obesity medication exclusion. Budget scorers have estimated the 10-year cost at $27 to $35 billion, depending on uptake assumptions, but proponents argue downstream savings in diabetes, cardiovascular events, and joint replacements would offset a significant fraction.

Limitations of Existing Economic Analyses

Several limitations apply to current cost-effectiveness estimates:

Short trial duration relative to disease chronicity. The 72-week randomized phase of SURMOUNT-3 captures weight loss and early metabolic improvements but cannot directly measure hard endpoints like myocardial infarction or mortality. Models must extrapolate from BMI-to-event risk equations, which may overestimate or underestimate benefit depending on whether weight loss via GLP-1 agonists carries the same risk reduction as weight loss through other means. The SELECT cardiovascular outcomes trial for semaglutide provides supportive evidence for the class, but no equivalent outcomes trial exists for tirzepatide in obesity without diabetes.

Weight regain assumptions drive results. Any model that assumes lifelong drug use will produce a higher total cost but better QALY accumulation than one assuming a defined treatment course. The reality is that many patients discontinue for reasons including cost, side effects, or perceived goal achievement. SURMOUNT-3 itself lost 12.4% of tirzepatide participants to discontinuation over 72 weeks; the per-protocol analysis showed even larger effect sizes, suggesting that completer populations may achieve better value per dollar spent.

Equity gaps are not captured. Standard CEA does not account for the distributional impact of coverage decisions. Obesity disproportionately affects lower-income and minority populations who are least likely to afford out-of-pocket costs or to have employer plans covering GLP-1 therapies.

No head-to-head economic comparison with semaglutide. The two agents have not been compared in a randomized trial. Cross-trial comparisons using SURMOUNT-3 and STEP-3 (semaglutide after lifestyle) suggest tirzepatide produces greater absolute weight loss, but whether the difference justifies any price premium remains unmodeled with adequate rigor.

The Individual Value Calculation

For a patient considering tirzepatide after successful lifestyle modification, the personal cost-effectiveness math is different from the societal one. Out-of-pocket costs range from $0 (with full insurance coverage) to $550+ monthly (self-pay vial pricing) to the full $1,060 WAC. At the self-pay price of approximately $550/month, a patient is spending $6,600 annually. The question becomes whether 21% total body-weight loss, compared to the roughly 3% they might maintain on lifestyle alone, is worth that expenditure in terms of quality of life, reduced medication burden for comorbidities, functional improvement, and long-term disease risk.

There is no universal answer. A patient with obesity-related type 2 diabetes spending $300/month on diabetes medications who achieves remission with tirzepatide-induced weight loss may see net savings. A patient without comorbidities paying entirely out of pocket faces a pure quality-of-life value judgment. Clinicians should discuss both the trial's efficacy data and the patient's specific financial and clinical context when framing this decision.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. Wadden TA, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 randomized clinical trial. Nat Med. 2023. PubMed
2. Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024. PubMed
3. Institute for Clinical and Economic Review (ICER). Anti-obesity medications: effectiveness and value. 2022 evidence report. PubMed
4. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023. PubMed
5. American Gastroenterological Association. Clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology. 2024. PubMed
6. Zepbound (tirzepatide) prescribing information. FDA. FDA Label